Related references
Note: Only part of the references are listed.TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer
Hai-ming Yu et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2014)
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Giuseppina Della Vittoria Scarpati et al.
ONCOTARGETS AND THERAPY (2014)
Mammaglobin-A Immunohistochemistry in Primary Central Nervous System Neoplasms and Intracranial Metastatic Breast Carcinoma
Patrick J. Cimino et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2014)
The soluble isoform of CTLA-4 as a regulator of T-cell responses
Frank J. Ward et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription
Arianne Perez-Garcia et al.
HUMAN IMMUNOLOGY (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
Stefania Laurent et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Leisha A. Emens
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
T-bet+ Treg Cells Undergo Abortive Th1 Cell Differentiation due to Impaired Expression of IL-12 Receptor β2
Meghan A. Koch et al.
IMMUNITY (2012)
Basic Science for the Clinician 55: CTLA-4
Leonard H. Sigal
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2012)
Circulating Soluble CTLA4 (sCTLA4) Is Elevated in Patients With Breast Cancer
Nasrollah Erfani et al.
CANCER INVESTIGATION (2010)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2010)
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
H. Mao et al.
CURRENT CANCER DRUG TARGETS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Increased CTLA-4 and FOXP3 Transcripts in Peripheral Blood Mononuclear Cells of Patients with Breast Cancer
Mansooreh Jaberipour et al.
PATHOLOGY & ONCOLOGY RESEARCH (2010)
Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y
V. A. L. Huurman et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
E Contardi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Negative co-receptors on lymphocytes
RJ Greenwald et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Share Paper
